NEW YORK, June 25, 2018 /PRNewswire/ -- This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million.Read the full report: https://www.reportlinker.com/p05443604
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as:- Alcobra Ltd.- Amarantus Bioscience Holdings, Inc.- Amedra Pharmaceuticals LLC- Curemark, LLC.- Eli Lilly and CompanyRead the full report: https://www.reportlinker.com/p05443604
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) THERAPEUTICS MCP-6195 A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSII. EXECUTIVE SUMMARY1. MARKET OVERVIEW ADHD Therapeutics: A Primer ADHD Therapeutics Market Outlook Factors Driving ADHD Therapeutics Market Changes in Insurance Coverage Addition of Formal Guidelines Low Diagnosis Threshold Advancements in Field of Medicine Unmet Needs Launch of Pipeline Drugs Factors Inhibiting ADHD Therapeutics Market Side Effects Related to Use of Stimulants to Treat ADHD Under-diagnosis of ADHD Condition Reduced Availability of Non-Stimulants in Certain Geographies Competitive Landscape Major ADHD Medications Available in the Market ADHD Medications Approved by FDA Patent Validity for Major ADHD Drugs 2. NOTEWORTHY TRENDS IN ADHD THERAPEUTICS MARKET Biological Psychiatry Gaining Ground Social Media Drives Heightened Awareness Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market Strategic Alliances 3. DEVELOPMENTAL PIPELINE OF ADHD DRUGS An Overview ADHD Drugs under Phase II/III Development in (2015) 4. ADHD - AN INSIGHT 5. CLINICAL TRIALS Supernus Announces Positive Results from Phase IIB Trials for SPN-812 Sunovion Announces Top-line Results from Phase II/III Clinical Trial Taisho Conducts Phase II Trial for TS-141 Shire Announces Positive Top-Line Result from Phase III Trial of SHP465-305 Highland Therapeutics Initiates Phase II Trial for HLD100 FDA Advises Hold for Alcobra Phase III Trial MDX for ADHD 6. PRODUCTS INNOVATIONS/INTRODUCTIONS Mylan Rolls Out Dextroamphetamine Sulphate Extended Release Capsules Tris Pharma Introduces Liquid DYANAVEL XR for ADHD Neos Introduces Adzenys XR-ODT Shire Introduces Intuniv, Non-Stimulant Treatment for ADHD Shire Introduces Elvanse Adult®, Stimulant Treatment for Adult ADHD Teva Adds Generic Intuniv® to Existing Line of ADHD Products FDA Approves Pfizer€™s QuilliChew ER„¢ Chewable Tablets Actavis Introduces Generic Version of Intuniv 7. RECENT INDUSTRY ACTIVITY Shire Files New Drug Application for Chewable Vyvanse Medgenics Acquires neuroFix Therapeutics 8. FOCUS ON SELECT GLOBAL PLAYERS Alcobra Ltd. (Israel) Amarantus Bioscience Holdings, Inc. (US) Amedra Pharmaceuticals LLC (US) Curemark, LLC. (US) Eli Lilly and Company (US) Intellipharmaceutics International, Inc. (US) Janssen Global Services, LLC (US) Mallinckrodt PLC (Ireland) Mylan N.V. (The Netherlands) Neos Therapeutics, Inc. (US) Neurovance, Inc. (US) Noven Pharmaceuticals, Inc. (US) Pfizer Inc. (US) Shire plc (Ireland) Supernus Pharmaceuticals, Inc. (US) Tris Pharma, Inc. (US) 9. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for ADHD Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 2: World Historic Review for ADHD Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 3: World 14-Year Perspective for ADHD Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III. MARKET1. THE UNITED STATES
A.Market Analysis US ADHD Therapeutics Market Set Firmly on Growth Trajectory Table 4: US ADHD Market: Prices of Select ADHD Drugs (2015) (includes corresponding Graph/Chart) US ADHD Prevalence Rate: Some Major Facts Table 5: ADHD with Co-existing Conditions (includes corresponding Graph/Chart) Major Trends Impacting the US ADHD Therapeutics Market Generics Ruling the Roost in US ADHD Therapeutics Market Table 6: US Market for ADFHD Drugs: Percentage Breakdown of Revenue for Stimulants and Non-stimulants (2015) (includes corresponding Graph/Chart) Adults on the Radar of US ADHD Drugs Manufacturers Table 7: US ADHD Drugs Market: Percentage Breakdown of ADHD Drug Prescriptions by Age Group & Gender (2015) (includes corresponding Graph/Chart) ADHD Drug for Adults: A Trail of Misuse, Addiction and Death More Prescriptions, More Issues Table 8: US ADHD Drugs Market: Prescriptions Filled (2010-2015) (includes corresponding Graph/Chart) More Drugs, More Complications, More Emergency Room Visits Though Small in Number, Deaths Due to ADHD Drug Complications is Rising ADHD in Children: A Case of One Diagnosis Too Many Individual Choices of Healthcare Professionals Influencing ADHD Diagnosis DSM 5„¢ Criteria DSM-5„¢ DIAGNOSTIC CRITERIA FOR ADHD Clinical Trials Products Launches Strategic Corporate Developments Select Major Players B.Market Analytics Table 9: The US Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 10: The US Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 2. CANADA
A.Market Analysis Current & Future Analysis Strategic Corporate Development B.Market Analytics Table 11: Canadian Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 12: Canadian Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 3. JAPAN
A.Market Analysis Increased Awareness Leading to Surge in Japanese ADHD Therapeutic Market Select ADHD Drugs in Pipeline in Japanese Market Strategic Corporate Development B.Market Analytics Table 13: Japanese Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 14: Japanese Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 4. EUROPE
A.Market Analysis Effective therapeutics and Rising Awareness Amongst Public Propelling European ADHD Market UK ADHD Market - An Overview ADHD Prevalence Table 15: ADHD Prevalence in the UK: Percentage Breakdown by Gender (Fiscal Year 2009-2010 through 2014-2015) Strategic Corporate Developments Select Key Players B.Market Analytics Table 16: European Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 17: European Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 5. ASIA-PACIFIC
A.Market Analysis Asia-Pacific ADHD Therapeutics Market on the Rise B.Market Analytics Table 18: Asia-Pacific Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 19: Asia-Pacific Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 6. LATIN AMERICA
A.Market Analysis Latin American ADHD Therapeutics Market to Cross US$3 billion
B.Market Analytics Table 20: Latin American Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 21: Latin American Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7. REST OF WORLD A.Market Analysis Current & Future Analysis ADHASA Enabling South African Children with ADHD to Chart New Course Strategic Corporate Development Alcobra Ltd. (Israel) - A Key Israeli Player B.Market Analytics Table 22: Rest of World Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 23: Rest of World Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 27 (including Divisions/Subsidiaries - 28) The United States (17) Canada (2) Japan (2) Europe (5) - The United Kingdom (1) - Rest of Europe (4) Middle East (2) Read the full report: https://www.reportlinker.com/p05443604
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-therapeutics-industry-300671692.html
SOURCE Reportlinker
